tradingkey.logo

tradingkey.logo
怜玢


Aquestive Therapeutics Inc

AQST
りォッチリストに远加
3.610USD
-0.050-1.37%
終倀 11-06 16:00ET
453.09M時䟡総額
損倱額盎近12ヶ月PER

Aquestive Therapeutics Incに぀いお 䌁業名

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Aquestive Therapeutics Inc プロフィヌル


䌁業コヌドAQST
䌚瀟名Aquestive Therapeutics Inc
䞊堎日Jul 25, 2018
最高経営責任者「CEO」Barber (Daniel R)
埓業員数142
蚌刞皮類Ordinary Share
決算期末Jul 25
本瀟所圚地30 Technology Dr
郜垂WARREN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号07059-5166
電話番号19089411900
りェブサむトhttps://aquestive.com/
䌁業コヌドAQST
䞊堎日Jul 25, 2018
最高経営責任者「CEO」Barber (Daniel R)

Aquestive Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Corporate Secretary
Corporate Secretary
517.40K
-40.94%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Chief People Officer
Chief People Officer
283.81K
+0.81%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-7.18%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
235.69K
--
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
205.15K
+2.24%
Dr. Matthew W. Davis
Dr. Matthew W. Davis
Chief Development Officer
Chief Development Officer
100.00K
+50.00%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Mrs. Abigail L. Jenkins
Mrs. Abigail L. Jenkins
Independent Director
Independent Director
19.00K
--
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John S. Cochran, CPA
Mr. John S. Cochran, CPA
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Corporate Secretary
Corporate Secretary
517.40K
-40.94%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Chief People Officer
Chief People Officer
283.81K
+0.81%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-7.18%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
235.69K
--
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
205.15K
+2.24%
Dr. Matthew W. Davis
Dr. Matthew W. Davis
Chief Development Officer
Chief Development Officer
100.00K
+50.00%

よくある質問

Aquestive Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Aquestive Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Ms. Lori J. Braender, J.D.

Aquestive Therapeutics IncAQSTの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Aquestive Therapeutics Incの株匏を保有しおいる機関は350瀟あり、保有株匏の総垂堎䟡倀は玄74.94Mで、党䜓の60.30%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-7481130.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。